| Pharmaceutical Information |
| Drug Name |
Luliconazole |
| Drug ID |
BADD_D01329 |
| Description |
Luliconazole is a topical antifungal agent that acts by unknown mechanisms but is postulated to involve altering the synthesis of fungi cell membranes. It was approved by the FDA (USA) in November 2013 and is marketed under the brand name Luzu. Luliconazole is also approved in Japan. |
| Indications and Usage |
|
| Marketing Status |
Prescription |
| ATC Code |
D01AC18 |
| DrugBank ID |
DB08933
|
| KEGG ID |
D01980
|
| MeSH ID |
C112528
|
| PubChem ID |
3003141
|
| TTD Drug ID |
D0U4XJ
|
| NDC Product Code |
68682-850; 66039-918; 70600-009; 99207-850; 60695-000 |
| Synonyms |
luliconazole | (2E)-((4R)-4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene)(1H-imidazol-1-yl)acetonitrile | 4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene-1-imidazolylacetonitrile | Lulicon | NND 502 | NND502 | NND-502 |
|
| Chemical Information |
| Molecular Formula |
C14H9Cl2N3S2 |
| CAS Registry Number |
187164-19-8 |
| SMILES |
C1C(SC(=C(C#N)N2C=CN=C2)S1)C3=C(C=C(C=C3)Cl)Cl |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
| ADR Term |
ADReCS ID |
ADR Frequency (FAERS)
|
ADR Severity Grade (FAERS)
|
ADR Severity Grade (CTCAE)
|
| Application site reaction | 12.07.01.006; 08.02.01.006 | - | - | Not Available | | Cellulitis | 23.09.01.001; 11.02.01.001 | - | - | Not Available | | Dermatitis contact | 23.03.04.004; 12.03.01.040; 10.01.01.003 | - | - | Not Available | | Tinea cruris | 23.09.02.003; 11.03.08.001 | - | - | Not Available | | Tinea pedis | 23.09.02.008; 11.03.08.004 | - | - | Not Available |
|
The 1th Page
1
Total 1 Pages
|
|
